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New knowledge added by this study
• The current project provided cost-effectiveness information for erlotinib and gefitinib based on four Asian 
phase-III clinical trials in non–small-cell lung cancer (NSCLC) patients using a threshold recommended by the 
World Health Organization. 
• The cost-effectiveness analysis indicates that erlotinib is cost-effective compared to gefitinib in first-line 
epidermal growth factor receptor (EGFR)–activating mutation-positive (MuT+) NSCLC patients in Hong 
Kong.
Implications for clinical practice or policy
• Erlotinib is efficacious and cost-effective, and hence should be considered a good option for treatment of EGFR 
MuT+ NSCLC patients.
• Being cost-effective, erlotinib should be considered for reimbursement by health care payers in Hong Kong.
A B S T R A C T 
Objective: To compare the effectiveness and cost-
effectiveness of erlotinib versus gefitinib as first-line 
treatment of epidermal growth factor receptor–
activating mutation-positive non–small-cell lung 
cancer patients.
Design: Indirect treatment comparison and a cost-
effectiveness assessment.
Setting: Hong Kong.
Patients: Those having epidermal growth factor 
receptor–activating mutation-positive non–small-
cell lung cancer. 
Interventions: Erlotinib versus gefitinib use was 
compared on the basis of four relevant Asian 
phase-III randomised controlled trials: one for 
erlotinib (OPTIMAL) and three for gefitinib 
(IPASS; NEJGSG; WJTOG). The cost-effectiveness 
assessment model simulates the transition between 
the health states: progression-free survival, 
progression, and death over a lifetime horizon. The 
World Health Organization criterion (incremental 
cost-effectiveness ratio <3 times of gross domestic 
product/capita: <US$102 582; approximately 
<HK$798 078) was used to rate cost-effectiveness.
Results: The best fit of study characteristics and 
prognostic patient characteristics were found 
between the OPTIMAL and IPASS trials. Comparing 
progression-free survival hazard ratios of erlotinib 
versus gefitinib using only these randomised 
controlled trials in an indirect treatment comparison 
resulted in a statistically significant progression-free 
survival difference in favour of erlotinib (indirect 
treatment comparison hazard ratio=0.33; 95% 
confidence interval, 0.19-0.58; P=0.0001). The cost-
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effectiveness assessment model showed that the 
cost per progression-free life year gained and per 
quality-adjusted life year gained was at acceptable 
values of US$39 431 (approximately HK$306 773) 
and US$62 419 (approximately HK$485 619) for 
erlotinib versus gefitinib, respectively. 
Conclusion: The indirect treatment comparison 
of OPTIMAL versus IPASS shows that erlotinib 
is significantly more efficacious than gefitinib. 
Furthermore, the cost-effectiveness assessment 
indicates that the incremental cost-effectiveness 
ratios are well within an acceptable range in relation 
to the survival benefits obtained. In conclusion, 
erlotinib is cost-effective compared to gefitinib for 
first-line epidermal growth factor receptor–activating 
mutation-positive non–small-cell lung cancer 
patients.
#  Erlotinib vs gefitinib in non–small-cell lung cancer  # 
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Introduction
Lung cancer is the leading cause of cancer deaths 
worldwide (1.38 million cancer deaths, 18.2% of the 
total) as well as of cancer morbidity (1.61 million 
new cases, 12.7% of all new cancers).1 Approximately 
80% to 85% of lung cancer patients have non–
small-cell lung cancer (NSCLC), and around 70% 
of these NSCLC patients present with advanced or 
metastatic disease (TNM stages IIIB/IV according 
to the American Joint Committee on Cancer2) at the 
time of diagnosis.3-6 Patients with late-stage NSCLC 
have a very poor prognosis; only about 7% with stage 
IIIB and 2% of those with stage IV survive beyond 5 
years.7 
 Evidently, NSCLC is a biological and genetic 
variant of lung cancer, which bears activating 
mutations in the tyrosine kinase domain of the 
epidermal growth factor receptor (EGFR). In 
Asian NSCLC patients, the frequency of activating 
EGFR mutations (EGFR MuT+) is estimated to 
be approximately 30% to 40%.6,8 Notably, EGFR 
mutations lead to structural changes, which stabilise 
the active form of the tyrosine kinase domain and 
result in a high affinity for binding EGFR tyrosine 
kinase inhibitors (TKIs).9 
 There are currently two small-molecule EGFR 
TKIs used in clinical practice and recommended as 
first-line treatment in patients with EGFR MuT+ 
NSCLC: erlotinib (Tarceva; F. Hoffmann-La Roche 
Ltd, Basel, Switzerland) and gefitinib (Iressa; 
AstraZeneca Ltd, London, UK).6,8
 Recently published analyses concluded that 
these EGFR TKIs appear to be the most effective 
therapy in treatment-naïve cancer patients with 
this mutation.10,11 As a result, both therapies are 
competing to be the primary choice in this clinical 
setting. 
 This poses the question as to whether there are 
differences in efficacy and cost-effectiveness between 
erlotinib and gefitinib. To answer this question and 
to offer guidance for physicians and health care 
payers, we undertook comparative effectiveness and 
cost-effectiveness assessments (CEAs) for the health 
care setting of Hong Kong. 
Underlying data
In order to base the research on the strongest available 
evidence, standard literature databases (PubMed, 
ASCO and ESMO congress databases) were screened 
for Asian randomised controlled phase-III trials that 
investigated the efficacy of erlotinib and gefitinib as 
first-line EGFR MuT+ NSCLC therapy. We included 
all Asian randomised controlled phase-III trials that 
investigated either gefitinib or erlotinib as first-line 
therapy of NSCLC, that have systematically assessed 
the EGFR mutation status of the included patients, 
and that have published sufficient information on the 
EGFR-mutation patient population characteristics 
目的：比較厄洛替尼（erlotinib）與吉非替尼（gefitinib）作為表皮生
長因子受體（EGFR）激活突變呈陽性的非小細胞肺癌香港患者的一
線治療的效用和成本效益。
設計：間接治療比較和成本效益評估。
安排：香港。
患者：EGFR激活突變呈陽性的非小細胞肺癌患者。
干預：在比較erlotinib與gefit inib的四個亞洲 III期隨機對照試
驗中，其中一個使用 e r l o t i n i b（O P T I M A L），另三個使用
gefitinib（IPASS、NEJGSG和WJTOG）。成本效益評估模型模擬健
康與疾病之間的過渡階段：即無惡化生存期、癌症惡化和死亡，並使
用世界衛生組織的準則（即增量成本效益比例少於人均國民生產總值
的三倍，相等於美元102 582或港幣約798 078）來計算其成本效益。
結果：OPTIMAL及IPASS試驗中的研究特性和病人預後特徵最為相
似。只針對這兩個隨機對照試驗，使用間接治療效果來比較erlotinib
與gefitinib的無惡化生存期的危險系數，發現erlotinib在無惡化生
存期方面較為優勝，結果差異具統計學意義（間接治療比較危險系
數=0.33；95%置信區間：0.19-0.58；P=0.0001）。把erlotinib與
gefitinib比較，成本效益評估模型顯示erlotinib的無惡化生存期以及生
活質量修正時間，每年需要的成本為39 431美元（即約港幣306 773
元），而gefitinib則為62 419美元（即約港幣485 619元），兩者均屬
可接受值。
結論：在OPTIMAL及IPASS試驗之間的間接治療比較顯示erlotinib
的療效比gefitinib優勝。此外，成本效益評估發現，對於生存優勢來
說，增量成本效益比率屬可接受範圍內。總而言之，對於EGFR激活
突變呈陽性的非小細胞肺癌患者來說，一線治療用erlotinib比gefitinib
較為符合成本效益。
厄洛替尼與吉非替尼作為表皮生長因子受體激活
突變呈陽性的非小細胞肺癌香港患者的一線治療
的效用和成本效益
李詠恩、Bjoern Schwander、李浩勳
and outcomes. By applying these criteria, four 
suitable Asian phase-III randomised controlled 
trials (RCT) were identified, one for erlotinib and 
three for gefitinib. 
 The OPTIMAL trial evaluated the efficacy and 
tolerability of erlotinib versus chemotherapy,12,13 
and the Iressa Pan-ASia Study (IPASS),14 the North-
East Japan Gefitinib Study Group trial (NEJGSG),15 
and the West Japan Thoracic Oncology Group 3405 
trial (WJTOG)16 evaluated the efficacy and safety 
of gefitinib vs chemotherapy. The following section 
provides the background information on these 
clinical trials, which is necessary as a basis for the 
planned comparative assessments. 
Study characteristics, study measurements, and 
patient characteristics
As shown in Table 1, the main study characteristics, 
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study measurements, and patient characteristics of 
the Asian EGFR TKI phase-III RCT for first-line 
treatment of EGFR MuT+ NSCLC were largely 
comparable but not identical.12,14-16 
 The best fit is encountered with the OPTIMAL 
and IPASS trials, as the tumour assessment 
periodicity (6 weekly for both OPTIMAL and 
IPASS), median age (57 years for both trials), 
performance status proportion (performance status 
0 or 1: OPTIMAL 92%, IPASS 90%), and the tumour 
stage distribution (stage IV: OPTIMAL 87%, IPASS 
86%) were comparable. In contrast, on comparing 
OPTIMAL versus the NEJGSG and WJTOG trials, 
differences were evident with respect to all of the 
above-named factors (Table 1). Such differences are 
important, as at least age, performance status, and 
tumour stage were predictors of progression-free 
survival (PFS) in NSCLC.7,17-19
Efficacy outcomes
All these phase-III RCT in first-line EGFR MuT+ 
NSCLCs have shown significant increases in 
the primary endpoint, namely PFS for erlotinib 
(OPTIMAL trial12) and gefitinib (IPASS14, NEJGSG15, 
WJTOG16) in comparison to standard chemotherapy. 
The erlotinib OPTIMAL trial reached a median PFS 
of 13.7 months and a corresponding hazard ratio 
(HR) of 0.16 with 95% confidence intervals (CI) of 
0.11-0.26 (P<0.0001).13 The gefitinib IPASS, NEJGSG, 
and WJTOG trials reached a respective median PFS 
of 9.5, 10.8, and 8.4 months with corresponding HRs 
of 0.48 (95% CI, 0.36-0.64; P<0.001), 0.30 (95% CI, 
Abbreviations: CB = carboplatin; CP = cisplatin; DOX = docetaxel; EGFR = epidermal growth factor receptor ; GEM = gemcitabine; 
MuT+ = mutation positive; NSCLC = non–small-cell lung cancer ; PAX = paclitaxel; PFS = progression-free survival; RCT = randomised 
controlled trial; TKI = tyrosine kinase inhibitor
* Subpopulation of patients with EGFR MuT+ NSCLC
† Subpopulation of patients with stage IIIB/IV NSCLC
‡ 10% of patients had earlier-stage NSCLC with a postoperative relapse
TABLE 1.  Comparison of the main study characteristics, study measurements, and patient characteristics of the Asian phase-III 
trials
Phase-III trial OPTIMAL12 IPASS14* NEJGSG15 WJTOG16†
EGFR TKI Erlotinib Gefitinib Gefitinib Gefitinib
No. of patients (EGFR TKI arm) 82 132 114 86
Chemotherapy comparator CB + GEM CB + PAX CB + PAX CP + DOX
Study characteristics
Study design RCT RCT RCT RCT
Blinding Open label Open label Open label Open label
Primary outcome PFS PFS PFS PFS
Tumour assessment 6 Weekly 6 Weekly 2 Monthly 2 Monthly
EGFR mutation status
Exon 19 mutation 52% 50% 51% 58%
Exon 21 mutation 48% 49% 43% 42%
Other 0% 1% 6% 0%
Race
Chinese 100% 31% 0% 0%
Japanese 0% 51% 100% 100%
Other East Asian 0% 18% 0% 0%
Age and gender
Median age (years) 57 57 64 64
Age range 31-74 34-82 43-75 34-74
Female (%) 58% 82% 63% 69%
Performance status (PS)
PS 0 or 1 92% 90% 99% 100%
PS ≥ 2 8% 10% 1% 0%
Tumour stage 
Stage IIIB 13% 14% 13%‡ 20%
Stage IV 87% 86% 77%‡ 80%
#  Erlotinib vs gefitinib in non–small-cell lung cancer  # 
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0.22-0.41; P<0.001), and 0.33 (95% CI, 0.20-0.54; 
P<0.0001).14-16
Tolerability outcomes
According to all four phase-III RCT, the EGFR 
TKIs showed a better tolerability profile than 
the chemotherapy comparators, and hence they 
appeared to confer less toxicity while achieving 
greater efficacy.12-16
 The most common serious adverse event 
(SAE) reported for erlotinib is elevation of alanine 
aminotransferase level (3.6%), which nevertheless 
compares favourably with gefitinib (27.6%).12,16 Other 
SAEs with the highest frequency for erlotinib also 
compare favourably with gefitinib, namely rash (2.4% 
vs 5.3%) and diarrhoea (1.2% vs 3.8%).12,14,15 Infection 
is the only SAE that has been reported for erlotinib 
(1.2%) but not in gefitinib trials.12 All other SAEs 
reported for gefitinib (aspartate aminotransferase 
elevation, neutropenia, fatigue, anaemia, anorexia, 
leukopenia, nausea, paronychia, and sensory 
disturbance) have not been reported for erlotinib. 
Irrespective of the small deviations observed when 
comparing the frequency of single adverse effects 
between erlotinib and gefitinib, the toxicity of these 
two TKIs can be regarded as comparable.12
Methods
Comparative effectiveness assessment
As both EGFR TKIs have shown favourable outcomes 
compared to chemotherapy, both are currently 
competing to be the primary choice in treatment-
naïve EGFR MuT+ NSCLC patients. Thus, in the 
absence of a direct head-to-head comparison, there 
is a need for an indirect comparative effectiveness 
assessment. 
 This assessment used the accepted and most 
widely applied indirect comparison methods 
introduced by Bucher et al in 1997.20 The Canadian 
Agency for Drugs and Technologies in Health21 
and others22,23 have identified this method as the 
most suitable approach for performing indirect 
comparisons of RCT outcomes. 
 According to the Bucher method,20 the 
chemotherapy comparator arm (C) of each trial 
has been used as a ‘bridge’ to connect and compare 
the efficacy of the investigational treatment arms, 
namely erlotinib (A) and gefitinib (B). The PFS HRs 
were selected as the basis for this indirect treatment 
comparison (ITC), as this efficacy measurement 
accounts for censoring and incorporates time-
to-event information.24 As an outcome of the 
comparative effectiveness assessment, the ITC HRs 
of erlotinib versus gefitinib are provided with 95% 
CIs. The applied ITC approach uses an effect size 
(PFS HR) that is expressed relative to the comparator 
(A vs C and B vs C; hence the comparator is used as a 
‘bridge’) to perform a so-called ‘adjusted ITC’ of the 
investigational treatment arms (A vs B). The related 
formula for the ITC HR is HRAB = HRAC /HRBC and 
the formula for the ITC 95% CI is HRAB ± 1.96 x 
SQRT(VAR[HRAB]).
 In order to test for statistical significance, 
P values were calculated by means of a two-sided 
Z test, using the methodology of Snedecor and 
Cochran 1989.25 The null hypothesis that the PFS 
of the compared therapy options is equal was to be 
rejected if P<0.05. All calculations were performed 
using Excel 2003. The ITC calculations could be 
re-performed using the ITC tool26 provided by the 
Canadian Agency for Drugs and Technologies in 
Health, thus ensuring maximum transparency. 
 Due to the good fit in prognostic patient 
characteristics, the key ITC was based on the 
OPTIMAL versus IPASS phase-III PFS HR 
outcomes. Furthermore, OPTIMAL was compared 
with the pooled Asian gefitinib evidence. This 
pooled evidence was obtained by applying a random 
effect pooling (PFS HR of gefitinib vs chemotherapy 
= 0.37; 95% CI, 0.27-0.51; P<0.0001) and a fixed 
effect pooling (PFS HR of gefitinib vs chemotherapy 
= 0.38; 95% CI, 0.31-0.46; P<0.0001) to the PFS HR 
outcomes of the IPASS, NEJGSG, and WJTOG trials. 
Cost-effectiveness assessment
Phase-III RCT evidence was used as the basis for 
the CEA. Evidence from OPTIMAL was used for 
erlotinib and evidence from IPASS for gefitinib, as 
these studies were the most comparable with respect 
to prognostic characteristics of the patients (Table 
1). 
 The CEA model uses a Markov approach that 
simulates the transition between the health states: 
PFS, progression and death, in monthly cycles and 
over a lifetime horizon. Patients with stage IIIB/
IV EGFR MuT+ NSCLC enter the model in PFS. 
Transition from PFS to progression is simulated 
by the published phase-III Kaplan-Meier estimates 
(erlotinib: OPTIMAL13; gefitinib: IPASS14). For 
the transition from progression to death, the same 
transition probability was applied for both EGFR 
TKIs using the final overall survival results from 
IPASS.27 This procedure was necessary, as OPTIMAL 
survival data are currently immature and follow-up 
is ongoing.12,13
 To estimate the Hong Kong–specific drug 
costs, the licensed dosage (same as in the phase-
III RCT) was applied; hence a daily dose of 150 mg 
for erlotinib and a daily dose of 250 mg for gefitinib 
were simulated. The drug costs per daily dose of 
US$74.94 for erlotinib and US$59.98 for gefitinib 
were based on gross ex-factory prices from October 
2011. In order to transfer the local currency (HK$) 
to US$, the average exchange rates (October 2010 to 
October 2011) from the Reserve Bank of Australia 
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were used (1 US$ = 7.78 HK$). These drug costs have 
been simulated until disease progression or death 
(therapy until progression). 
 In order to simulate quality-adjusted life years 
(QALYs), published health utility values according to 
Nafees et al28 were applied to the health states of PFS 
(0.653) and progression (0.473). A health utility of 
zero (0) was applied to the health state of death. The 
CEA outcomes were expressed as cost per life year 
gained, cost per progression-free life year (PF-LY) 
gained, and as cost per QALY gained for erlotinib 
and gefitinib. The simulation results were based on 
a Monte-Carlo simulation using 1000 iterations; 
all simulations were performed in Excel 2003. 
Costs and effects have been discounted by 3% per 
annum according to regional pharmacoeconomic 
recommendations.29 Sensitivity analyses of the 
treatment effect on the cost-effectiveness results 
were performed by applying the extreme bounds 
(lower and upper 95% CIs) of the PFS Kaplan-Meier 
estimates for erlotinib and gefitinib. 
 The World Health Organization (WHO) 
criterion (incremental cost-effectiveness ratio 
[ICER] <3 times of the Hong Kong GDP/capita,30 
which gave a figure of <US$102 582 or approximately 
<HK$798 078) was used for this purpose.31
Results
Comparative effectiveness assessment
Comparing the PFS HRs of erlotinib versus gefitinib 
in first-line EGFR MuT+ NSCLC based on OPTIMAL 
and IPASS resulted in a statistically significant PFS 
difference in favour of erlotinib (ITC HR=0.33; 
95% CI, 0.19-0.58; P=0.0001). As shown in Figure 
1, comparing erlotinib versus the pooled gefitinib 
phase-III evidence confirmed these findings.
Cost-effectiveness assessment
According to the CEA model outcomes, erlotinib 
was more effective in terms of life years gained, 
PF-LY gained, and QALYs gained when compared 
with gefitinib in first-line EGFR MuT+ NSCLC 
therapy (Table 2).
 The therapy costs of erlotinib were higher than 
those of gefitinib, as shown in Table 2. Besides higher 
daily therapy costs, the superior efficacy of erlotinib 
was the reason for this cost difference. The longer 
time in PFS compared with gefitinib increased its 
total therapy duration (therapy until the disease 
progressed or death), which translated into higher 
total costs.
 To determine whether the additional total 
therapy costs of erlotinib therapy were reasonable 
in relation to the efficacy benefit obtained, an 
incremental cost-effectiveness analysis was 
performed. The cost per life year gained by erlotinib 
was US$41 494 (incremental costs US$14 061/
incremental life years 0.34), the cost per PF-LY 
gained by erlotinib was US$39 431 (incremental 
costs US$14 061/incremental PF-LY 0.36), and the 
cost per QALY gained by erlotinib was US$62 419 
FIG 1.  Comparative effectiveness assessment results of erlotinib versus gefitinib
Abbreviations: CI = confidence interval; FE = fixed effect; HR = hazard ratio; ITC = 
indirect treatment comparison; RE = random effect 
TABLE 2.  Overview of discounted cost-effectiveness assessment (CEA) model base 
case results simulated on the basis of the OPTIMAL and IPASS phase-III randomised 
controlled trials
CEA model outcome Erlotinib Gefitinib Incremental
Life years 2.16 1.82 0.34
Progression-free life years 1.15 0.79 0.36
Quality-adjusted life years 1.23 1.00 0.23
Total costs (US$) 31 434 17 373 14 061
Key indirect treatment comparison
ITC HR
0.00 0.50 1.00 1.50 2.00
Favours erlotinib Favours gefitinib
OPTIMAL vs IPASS
OPTIMAL vs pooled gefitinib (FE)
OPTIMAL vs pooled gefitinib (RE)
ITC HR (95%CI)
0.33 (0.19-0.58)
0.42 (0.27-0.68)
0.43 (0.25-0.74)
P value
P=0.0001
P=0.0004
P=0.0024
Pooled Asian gefitinib evidence
FIG 2.  Incremental cost-effectiveness base case results of erlotinib versus gefitinib
Abbreviations: LY = life year ; PF-LY = progression-free life year ; QALY = quality-
adjusted life year ; WHO = World Health Organization
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(incremental costs US$14 061/incremental QALY 
0.23) [Fig 2].
 These ICERs were well within a range 
usually regarded as cost-effective using WHO 
cost-effectiveness criteria. According to these, a 
therapy is ‘highly cost-effective’ if the ICERs are 
less than the gross domestic product (GDP) per 
capita (<US$34 194), ‘cost-effective’ if the ICERs are 
between 1 (US$34 194) and 3 times (US$102 582) 
the GDP per capita, and ‘not cost-effective’ if more 
than 3 times the GDP per capita (>US$102 582).
 As shown in Table 3, sensitivity analyses 
on the treatment effect confirmed the robustness 
of the cost-effectiveness outcomes as almost all 
ICERs remained below the WHO cost-effectiveness 
threshold (<US$102 582).
Discussion
To offer guidance for physicians and health care 
payers, comparative effectiveness and CEAs were 
Abbreviations: 95% CI = 95% confidence interval; ERL = erlotinib; GEF = gefitinib; ICER = incremental cost-effectiveness ratio; PFS = 
progression-free survival
TABLE 3.  Overview of discounted cost-effectiveness assessment model sensitivity analyses results simulated on the basis of the 
OPTIMAL and IPASS phase-III randomised controlled trials
Erlotinib Gefitinib Incremental ICER
Base case
Total costs (US$) 31 434 17 373 14 061
Life years 2.16 1.82 0.34 41.356
Progression-free life years 1.15 0.79 0.36 39.058
Quality-adjusted life years 1.23 1.00 0.23 61.135
Best PFS (upper 95% CI PFS)
Total costs (US$) 37 638 22 327 15 311
Life years 2.37 2.03 0.34 45.032
Progression-free life years 1.37 1.02 0.35 43.746
Quality-adjusted life years 1.37 1.15 0.22 69.595
Worst PFS (lower 95% CI PFS)
Total costs (US$) 24 434 14 426 10 008
Life years 1.91 1.69 0.22 45.491
Progression-free life years 0.89 0.66 0.23 43.513
Quality-adjusted life years 1.07 0.92 0.15 66.720
Best PFS (ERL) vs base case (GEF)
Total costs (US$) 37 638 17 373 20 265
Life years 2.37 1.82 0.55 36.845
Progression-free life years 1.37 0.79 0.58 34.940
Quality-adjusted life years 1.37 1.00 0.37 54.770
Best PFS (GEF) vs base case (ERL)
Total costs (US$) 31 434 22 327 9107
Life years 2.16 2.03 0.13 70.054
Progression-free life years 1.15 1.02 0.13 70.054
Quality-adjusted life years 1.23 1.15 0.08 113.838
Worst PFS (ERL) vs base case (GEF)
Total costs (US$) 24 434 17 373 7 061
Life years 1.91 1.82 0.09 78.456
Progression-free life years 0.89 0.79 0.10 70.610
Quality-adjusted life years 1.07 1.00 0.07 100.871
Worst PFS (GEF) vs base case (ERL)
Total costs (US$) 31 434 14 426 17 008
Life years 2.16 1.69 0.47 36.187
Progression-free life years 1.15 0.66 0.49 34.710
Quality-adjusted life years 1.23 0.92 0.31 54.865
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performed to compare erlotinib versus gefitinib in 
the treatment of treatment-naïve patients with EGFR 
MuT+ NSCLC in the health care setting of Hong 
Kong. Both the comparative assessments used state-
of-the-art methods; however, specific limitations 
had to be taken into account.
 The main limitation related to these 
comparative effectiveness assessments was that 
our findings were based on indirect evidence. Such 
ITCs have to be regarded as complementary to 
clinical trials, because they cannot substitute direct 
evidence. However, in the absence of any head-to-
head comparison, the ITC approach can be regarded 
as the most valuable way of estimating comparative 
treatment effects in a statistically accurate manner.
 Another limitation was the difference in 
prognostic patient characteristics between the 
phase-III trials used. Whereas OPTIMAL and 
IPASS showed a relatively good fit, the OPTIMAL 
versus NEJGSG or WJTOG comparisons showed a 
mismatch of prognostic factors. For this reason, the 
comparative effectiveness assessment used only the 
OPTIMAL and the IPASS trials as a basis for the key 
comparison. Focusing on this key comparison was a 
necessary precondition for the validity of the ITC, as 
it ensured that the results were primarily influenced 
by the treatment effect and not the ‘base risk profiles’. 
To avoid this confounding factor, the NEJGSG 
and the WJTOG trials were only considered in a 
pooled gefitinib PFS HR analysis, which confirmed 
the findings of the key comparison (OPTIMAL vs 
IPASS). 
 Another Asian study, namely the First-SIGNAL 
study,32 was excluded from our assessment because 
relevant details on the EGFR MuT+ subpopulation 
were not published. Besides, the EGFR MuT+ status 
in this study was assessed only in a limited number 
of patients and the trial failed to meet its primary 
endpoint. However, an inclusion of First-Signal study 
would have worsened the pooled gefitinib results 
presented in our assessment, as the PFS HR obtained 
for the EGFR MuT+ population in First-SIGNAL study 
was the highest obtained within each gefitinib study 
(PFS HR=0.54; 95% CI, 0.27-1.10) and did not reach 
statistical significance compared to chemotherapy. 
 For erlotinib, there was another phase-III RCT 
available named EURTAC that was performed in a 
European patient population, and resulted in a PFS 
HR of 0.37 (95% CI, 0.25-0.54),33 which was not 
included in our assessment. Compared with patients 
in the Asian phase-III gefitinib trials,14-16 patients in 
the EURTAC trial33 had the highest median age, the 
highest proportion with a worse performance status, 
and the highest proportion with stage IV disease, 
apart from using a Caucasian patient population 
which in itself was an important prognostic 
factor.34-36 Thus, according to these prognostic 
patient characteristics, the only phase-III trial 
performed in Caucasian patients (EURTAC) was not 
comparable to any other phase-III trial and hence 
warranted assessment separately from the Asian 
evidence. Notably, this was our rationale for basing 
our assessment for the Hong Kong health care 
setting on the available Asian evidence only. 
 The median PFS values of the chemotherapy 
comparator arms of the selected Asian phase-
III trials were 4.6 months in OPTIMAL,12,13 5.4 
months in NEJGSG,15 and 6.3 months in the IPASS14 
and WJTOG.16 These differences in the median 
PFS times of chemotherapy have raised doubts 
about the PFS HRs of the OPTIMAL trial, since it 
seemed that erlotinib treatment was compared to a 
comparator arm with the worst performance. This 
is a frequently applied misinterpretation of the data, 
as the median PFS values reflect only one point in 
time in the PFS Kaplan-Meier curve. In order to 
determine whether one chemotherapy arm shows a 
better performance than the other (eg comparison 
between the OPTIMAL chemotherapy arm and the 
IPASS chemotherapy arm), a comparison of both 
chemotherapy PFS curves over time on the basis 
of patient level data from both clinical studies is 
required. Our comparison approach was based on 
the HRs (the standard measure for determining the 
efficacy of oncology drugs), which reflects the area 
between the PFS Kaplan-Meier curves of the EGFR 
TKIs versus the chemotherapy comparators, taking 
into account the whole study period, hence it is not 
influenced by the different median PFS values. 
 A possible reason for the PFS difference 
observed between the two EGFR TKIs might be 
related to the differences in the chemical structure of 
erlotinib and gefitinib. These structural differences 
influence the metabolism of the two drugs by the 
human liver enzymes. Erlotinib is less susceptible 
to the metabolizing enzymes than gefitinib and 
therefore, at an approved dose of 150 mg once daily, it 
achieves approximately a 3.5-fold higher steady-state 
plasma concentration than gefitinib administered at 
the recommended dose of 250 mg once daily.37 This 
higher circulating level of erlotinib might provide 
a clinical advantage over gefitinib38 and explain the 
better efficacy of erlotinib39 compared with gefitinib 
in the treatment-naïve Asian EGFR MuT+ NSCLC 
patients. 
 One limitation of the CEA performed was that 
total therapy costs were only estimated on the basis 
of drug costs. In order to perform an adequate total 
cost assessment, further cost components such as 
prescription costs, adverse effect costs, and EGFR 
mutation testing costs usually have to be taken into 
account. However, as the cost-effectiveness analysis 
was based on an incremental assessment of erlotinib 
versus gefitinib, the correctness of results depended 
on assessing all relevant differences in costs. These 
differences were considered adequately reflected 
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by differences in drug costs and differences in the 
therapy duration (difference in PFS) simulated. 
The rationale for this was that both therapies have 
comparable prescription and EGFR testing costs, 
which make no difference when calculating the 
incremental costs between the two therapies. Only 
the costs of adverse effects might influence the 
incremental costs. However, these costs are hard 
to assess. Although erlotinib shows less SAEs than 
gefitinib, the difference in the related costs in favour 
of erlotinib was estimated to be minor. 
 Another limitation of the cost-effectiveness 
analysis was the assumption that both TKI therapies 
present a similar survival probability after disease 
progression. The survival probability after disease 
progression was simulated on the basis of the 
IPASS overall survival outcomes. This assumption 
was necessary, as the overall survival results 
from OPTIMAL are still immature. As a result 
of this assumption, the PFS benefit of erlotinib 
was transferred to the overall survival outcome. 
How strongly this assumption impacts the results 
is currently difficult to determine. Future CEAs 
using the final OPTIMAL overall survival data 
(currently immature) are necessary to eliminate this 
uncertainty.
 Furthermore, the cost-effectiveness results 
are not transferable to other health care settings, as 
they are dependent on country-specific drug prices. 
Hence, the results presented have to be regarded as 
specific to the health care setting of Hong Kong and 
any possible similar findings in other countries and 
health care settings need to be confirmed in separate 
analyses.
 To the authors’ knowledge, this is the first 
ITC and CEA performed for treatment-naïve EGFR 
MuT+ NSCLC in Asian patients. Hence, currently 
there are no other publications confirming or 
conflicting  with these findings.
Conclusion
The CEA for Hong Kong showed that the cost per 
life year gained, the cost per PF-LY gained, and the 
cost per QALY gained by erlotinib were well within 
an acceptable range in relation to the survival benefit 
obtained. In conclusion, erlotinib was cost-effective 
compared to gefitinib as first-line EGFR MuT+ 
NSCLC in Hong Kong.
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